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Abstract 
 
 
Introduction: We report a cost-effectiveness evaluation of granulocyte colony– 
stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) after 
chemotherapy in the United Kingdom (UK). 
 
Methods: A mathematical model was constructed simulating the experience of 
women with breast cancer undergoing chemotherapy. Three strategies were 
modelled: primary prophylaxis (G-CSFs administered in all cycles), secondary 
prophylaxis (G-CSFs administered in all cycles after an FN event), and no G-CSF 
prophylaxis. Three G-CSFs were considered: filgrastim, lenograstim, and 
pegfilgrastim. Costs were taken from UK databases and utility values from published 
sources. A systematic review provided data on G-CSF efficacy. Probabilistic sensitivity 
analyses examined the effects of uncertainty in model parameters. 
 
Results: In the UK, base-case analysis with a willingness-to-pay (WTP) threshold of 
£20,000 per quality-adjusted life-year gained and using list prices, the most cost- 
effective strategy was primary prophylaxis with pegfilgrastim for a patient with 
baseline FN risk greater than 38%, secondary prophylaxis with pegfilgrastim for 
baseline FN risk 11% to 37%, and no G-CSFs for baseline FN risk less than 11%. Using 
a WTP threshold of £30,000 and list prices, primary prophylaxis with pegfilgrastim 
was cost-effective for baseline FN risks greater than 29%. In all analyses, 
pegfilgrastim dominated filgrastim and lenograstim. Sensitivity analyses 
demonstrated that higher WTP threshold, younger age, earlier stage at diagnosis, or 
reduced G-CSF prices result in G-CSF prophylaxis being cost-effective at lower 
baseline FN risk levels. 
 
Conclusion: Pegfilgrastim was the most cost-effective G-CSF. The most cost-effective 
strategy (primary or secondary prophylaxis) was dependent on the FN risk level for 
an individual patient, patient age and stage at diagnosis, and G-CSF price. 
 
Key words: Cost-effectiveness; economic model; febrile neutropenia; granulocyte 
colony–stimulating factors; prophylaxis. 
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INTRODUCTION 
 
Neutropenia is the major dose-limiting toxicity of many chemotherapy regimens. 
Febrile neutropenia (FN) and its consequences are associated with substantial 
morbidity, mortality, and costs.(1) Chemotherapy-induced neutropenia and FN are 
also associated with dose reductions and delays to chemotherapy that can 
compromise patient survival.(2) 
 
In the UK the National Confidential Enquiry into Patient Outcome and Death 
(NCEPOD) performed a review of the care of patients who died within 30 days of 
receiving systemic anti-cancer therapy (SACT).(3) They report that the most 
commonly reported grade 3-4 toxicities associated with patients dying within 30 
days of chemotherapy were neutropenia, neutropenic sepsis and infection. 
 
Recombinant human granulocyte colony-stimulating factors (G-CSFs) stimulate 
production of mature, functional neutrophils (4) which reduce the duration and 
severity of neutropenia and the incidence of FN when used as prophylaxis alongside 
chemotherapy.(5;6) G-CSF prophylaxis may be beneficial during treatment for many 
different cancers, depending on the risk of FN which is a factor of combined 
chemotherapy regimen and patient risk factors.(7) This analysis focuses on breast 
cancer as the evidence base for G-CSF prophylaxis is well developed in this setting. 
Three G-CSFs were in use at the time of this analysis: filgrastim, pegfilgrastim, and 
lenograstim. Pegfilgrastim is given as a single injection per chemotherapy cycle. 
Filgrastim and lenograstim prophylaxis both involve administration of a number of 
daily injections per cycle. It is recommended that filgrastim and lenograstim are 
given daily until the neutrophil count returns to the normal range (for up to 14 days 
per cycle for filgrastim, or up to 28 days for lenograstim).(8;9) 
 
G-CSFs can be administered as primary prophylaxis (in all cycles) or as secondary 
prophylaxis (in all remaining cycles following an episode of FN). A 2003 UK audit of 
422 breast cancer patients found that only 3.6% of patients received prophylactic G- 
CSFs and all use was as secondary prophylaxis.(10) The introduction of newer breast 
cancer chemotherapy regimens such as TAC (docetaxel, doxorubicin, and 
cyclophosphamide) and FEC-T (fluorouracil, epirubicin, and cyclophosphamide, 
docetaxel) associated with higher FN risks may further increase the need for primary 
prophylaxis.(11) 
 
Clinical guidelines on the use of G-CSFs have been produced by the European 
Organisation for Research and Treatment of Cancer (EORTC)(7) and also in the US by 
the American Society of Clinical Oncology (ASCO)(12) and the National 
Comprehensive Cancer Network (NCCN) (13). All sets of guidelines recommend that 
prophylactic G-CSFs should be used where the risk of FN associated with the 
chemotherapy regimen is greater than or equal to 20%, and may be considered 
where the risk is 10-20%, particularly where additional patient risk factors are 
present. 
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The objective of this study is to model the cost-effectiveness of G-CSF prophylaxis of 
FN in patients with breast cancer compared with no G-CSF provision. In the analyses 
seven prophylaxis strategies are evaluated: primary prophylaxis and secondary 
prophylaxis for each of three G-CSFs (pegfilgrastim, filgrastim and lenograstim) and 
no G-CSF prophylaxis. 
 
 
 
METHODS 
 
Model structure 
 
A mathematical model was constructed using TreeAge Software (TreeAge Software 
Inc, USA) to estimate the costs and quality adjusted life years (QALYs) accrued by 
different strategies of G-CSF use. The model provided the basis for a submission to 
the All Wales Medicines Strategy Group, and this body subsequently recommended 
pegfilgrastim for use both as primary and secondary prophylaxis in the NHS in 
Wales.(14) A lifetime horizon was used as an FN episode may impact on patient 
survival. 
 
The modelling approach conforms to the National Institute for Health and Clinical 
Excellence (NICE) methods guidance. (15) The model takes the perspective of the UK 
National Health Service (NHS) and was populated with UK data where possible. A 
meta-analysis was performed to obtain efficacy data, EQ-5D utility values were used, 
and future costs and benefits were discounted at a rate of 3.5% per annum. 
 
The base case for the analysis consisted of a cohort of 52 year old female patients 
diagnosed with stage 2 breast cancer in line with data on presenting 
characteristics.(16) (17) In line with the NICE reference case, willingness-to-pay 
(WTP) thresholds of £20,000 and £30,000 were used (15) to calculate net monetary 
benefit (NMB). 
 
The majority of clinical trials of filgrastim and lenograstim alongside chemotherapy 
cycles of 3-week duration used approximately 11 injections per cycle, by which point 
the neutrophil count had generally recovered.(5;18;19) Therefore we have assumed 
that 11 days’ treatment with either lenograstim or filgrastim is consistent with the 
efficacy evidence reported within the RCTs. 
 
Several FN risk factors and breast cancer survival risk factors are included in the 
modelling and these relations are shown in Figure 1, and discussed below. 
 
The model structure is shown in Figure 2. A regimen consisting of 6 chemotherapy 
cycles of 21 days each is modelled, and in each chemotherapy cycle a patient may or 
may not experience an FN event. A regimen of 6 cycles was modelled because this is 
the number of cycles commonly given for breast cancer in the UK. An FN event may 
cause chemotherapy dose delays/reductions (i.e. sub-optimal relative dose intensity, 
RDI) which may affect patient survival. Post-chemotherapy, the model uses a state 
transition model with a cycle length of 1 year. Life expectancy is estimated using 
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breast cancer survival data (which is dependent on stage at diagnosis). Patients may 
die of FN during chemotherapy and from breast cancer or other causes after 
chemotherapy. During chemotherapy only deaths due to FN are considered but post 
chemotherapy deaths from breast cancer and other causes are considered. 
 
One and two way sensitivity analyses were undertaken. Probabilistic sensitivity 
analyses (PSA) were run using 10,000 sets of parameters sampled independently 
from the distributions described in Table 3. Distributions used were taken from 
published sources where available and otherwise they were chosen to fit to 
published 95% confidence intervals. Further details on choice of distributions are 
given in the data population section. The appropriateness of 1,000 configurations 
was tested using jack-knife techniques,(20) which on an example dataset showed 
that the confidence interval around a mean cost per QALY was small (less than £500 
in all cases). 
 
Data Population 
 
Calculating FN risk for patients receiving no prophylaxis 
Baseline risk, defined as the likelihood of having at least one FN episode over all 
cycles of chemotherapy without G-CSF provision, can vary widely amongst patients. 
The EORTC guidelines show that baseline risk can vary from 1% to 71%, depending 
on chemotherapy regimen, patient age, performance status, and other risk 
factors.(7) It has also been established that the risk of an initial FN episode is 
greatest in chemotherapy cycle 1.(6;21;22) The relative risk of an initial FN event in 
cycles 2 onwards compared with cycle 1 was calculated as 0.2 (95% CI: 0.154 – 0.293) 
using data from a study which distinguished between initial and subsequent FN 
events.(21) In addition, occurrence of an FN event indicates that a patient is at a 
higher risk of further FN events in subsequent cycles. The relative risk of further FN 
episodes in a patient with prior episodes was calculated as 9.09 (95% CI 6.19-13.35), 
using data from a study which reported first occurrence of FN events by cycle.(21) 
Lognormal distributions fitted to these confidence intervals were used for these FN 
related relative risks. 
 
To inform decision-making for a broad population of patients, we modelled the cost- 
effectiveness of G-CSF for a range of baseline risk values. Our model required the FN 
risk per cycle, which we calculated from the baseline risk using the information given 
above, and assuming 6 cycles of chemotherapy. For example, to model a baseline FN 
risk of 20%, this was split into a cycle 1 risk of 10% and a risk of 2% for each of cycles 
2-6. If a patient had an FN episode in cycle 1, this increased the FN risk in each 
subsequent cycle to 18%. Further details on these calculations are given in Appendix 
1. 
 
G-CSF efficacy 
A full systematic review of literature relating to G-CSF efficacy was undertaken. The 
comparative efficacy of the three G-CSFs in reducing FN risk is evaluated using meta- 
analyses of trials of each G-CSF compared with no primary G-CSF prophylaxis (see 
Table 1). This work updated an existing meta-analysis by Kuderer et al. (23) and will 
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be published separately. Details of the trials of the pegfilgrastim versus no GCSF are 
included in Appendix 2. In line with NICE methods guidance the results of the meta- 
analysis were used in the base-case analysis. Lognormal distributions fitted to the 
confidence intervals from the meta-analysis were used to represent uncertainty in G- 
CSF efficacy relative risk values. 
 
In general the studies included in the meta-analysis by Kuderer et al(23) described 
administration of filgrastim/lenograstim for approximately 11 days where the 
chemotherapy cycle length was three weeks. The use of filgrastim and lenograstim 
for 6 days was also considered as a 2003 UK audit of breast cancer patients found 
that such a regimen is sometimes used, although the number of patients in this audit 
was small (n=15).(10) A US observational study of 205 breast cancer patients also 
found that patients received on average 6 days of filgrastim per cycle.(24) Clinically it 
is expected that 6-day filgrastim is less efficacious than 11-day filgrastim since trial 
evidence indicates that neutrophil count does not fully recover until around 11 days 
of filgrastim treatment.(5;18;19) Trial evidence relating to using filgrastim or 
lenograstim for six days is limited and inconclusive. (25) (21) We have therefore 
conservatively assumed the efficacy for 6-day use to be the same as that for 11-day 
use; this assumption is favourable to the 6-day strategy. 
 
Mortality rates used within the model 
A study by Kuderer et al analysed 3,077 breast cancer patients hospitalised for FN in 
the US between 1995 and 2000.(1) The mortality rate from FN for breast cancer 
patients was 3.6% (95% CI 2.9% to 4.3%) and a normal distribution was used to 
model uncertainty. 
 
Breast cancer survival data are dependent on stage of diagnosis and years since 
diagnosis. Data from Cancer Research UK 2007 for patients diagnosed in 1985 gives 
survival rates by cancer stage at diagnosis and years since diagnosis; with survival 
rates at 10 years of 78%, 55%, 28% and 5% for stages 1-4 respectively.(26) More 
recent survival data from 2001-2003 reports breast cancer survival at 1, 5, 10, 15 and 
20 years as 94%, 80%, 72%, 68% and 65% respectively for all stages combined.(27) 
The relative proportion of patients in each stage at diagnosis is 39%, 48%, 8% and 5% 
for stages 1 to 4 respectively (28) and it was assumed that improvements in survival 
since 1985 affect all stages equally. After adjustment, breast cancer survival rates at 
10 years were calculated as 86%, 70%, 46% and 16% for stages 1-4 respectively. 
 
A limitation of the above data is that it relates to all breast cancer patients, not just 
those who undergo chemotherapy. It is not clear in which direction this will bias 
results as the fact that a patient is receiving chemotherapy may indicate a good 
performance status but it may also indicate advanced disease and hence an 
increased risk of mortality. 
 
Mortality due to other causes is taken from Office for National Statistics data.(16) 
 
Reduced relative dose intensity (RDI) of chemotherapy 
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Reduced RDI is commonly defined as receipt of <85% of the planned chemotherapy 
dose intensity (either as a result of a reduced dose or a delay between doses).(2;29) 
Being aged 65 years or older and having a history of an FN event are both predictors 
of receiving a reduced RDI.(2;30) As age is also a predictor of FN,(30) age and FN are 
not independent as predictors of RDI. The correlation between these variables was 
explicitly modelled by Shayne et al using a multivariate logistic regression analysis.(2) 
The reported odds ratios were used to calculate the risk of having a reduced RDI for 
the following four groups: age < 65 years without a prior FN event, age<65 years 
with a prior FN event, age ≥65 years without a prior FN event, and age ≥65 with a 
prior FN event; see Table 2. Log-normal distributions were used to model uncertainty 
in these odds ratios. 
 
Impact of RDI on survival 
The relationship between chemotherapy dose intensity and survival is uncertain. 
However, it is generally considered that a reduction in RDI below the optimum is 
likely to be detrimental to long-term survival from cancer.(29) In particular, in 
situations where dose-dense or dose-intense chemotherapy strategies are used 
reduction in RDI may be detrimental to survival. (7) 
 
Estimations can be made either from prospective trials that try to determine optimal 
dose or from retrospective studies but both have limitations. In prospective studies 
there is likely to be a ceiling above which further dose increases will not increase 
survival. Long-term retrospective studies may be confounded by the fact that 
patients who have their dose intensity reduced may be those who are more likely to 
die due to other factors such as older age and poorer performance status. A 
retrospective study by Chirivella et al. reports a hazard ratio of 1.73 for survival 
associated with RDI >=85% versus RDI<85%.(31) In this study 88% of patients received 
RDI >=85% and 12% received RDI<85%. 
 
The reciprocal of the reported HR was used to estimate mortality rates for low and 
high RDI from the mean age dependent mortality rate as follows: 
 
Mean mortality = (probability RDI <85%)*(mortality if RDI <85%) 
+ (probability of RDI >=85%)*(mortality if RDI >=85%). 
 
Hence rearranging we get: 
Mortality if RDI <85%  = mean mortality/(12%+88%*HR), and 
Mortality if RDI >=85% = mean mortality*HR/(12%+88%*HR). 
 
The model applies this hazard ratio to survival of patients with low RDI for the 
remainder of their lifetime. As mentioned above the retrospective nature of the 
Chirivella study may result in confounding. For this reason a sensitivity analysis in 
which low RDI has no effect on survival has been included. 
 
Utility values 
Utility values which are dependent on both health state and patient age were used. 
The average population utilities, categorised by age, have been taken from Kind et 
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al.(32) Each adverse health state (FN, receiving chemotherapy for breast cancer, local 
or regional recurrence, distant metastases and disease free) is assumed to be 
associated with a decreased utility for the duration of the event. Each chemotherapy 
cycle is assumed to last for 3 weeks and the mean length of hospitalisation following 
an FN event is estimated to be 8 days. (1) 
 
Utility values for the health states “FN” and “receiving chemotherapy for breast 
cancer” were reported as 0.33 and 0.70.(33) (34;35) These were converted into 
utility multipliers of 0.398 and 0.843 (by dividing by 0.83 the age factor for age 
55,(32) assuming published utility is for patients aged 55). Utility multipliers for 
disease-free state, local or regional recurrence and distant metastases were taken 
from Hind et al 2007; see Table 3.(36) For cancer survivors in years 1-5 it is assumed 
that 77% are disease free, 7% have local or regional recurrence and 16% have distant 
metastases.(36) These proportions were combined with the relevant multipliers to 
produce an average utility multiplier of 0.855. For cancer survivors in years 6-20 it is 
estimated from ONS survival data that 81% are disease free, 9.5% have local or 
regional recurrence and 9.5% have distant metastases hence an average utility 
multiplier of 0.879 was used. For 20+ years post-diagnosis, it was assumed that 
patients were disease-free and a utility multiplier of 0.94 was used. Beta 
distributions were used to model uncertainty in utility values. 
 
Valuation of Costs 
All cost parameters were taken from UK sources. For other parameter values where 
UK data sources were not available the best quality non-UK data sources identified 
were used. Only costs incurred during the time on chemotherapy are included in the 
model. It was assumed that costs incurred after chemotherapy was completed were 
independent of G-CSF prophylaxis strategy. 
 
The unit costs used within the model are given in Table 3. It is assumed that G-CSF 
injections are administered by a district nurse at the patient’s home. It is assumed 
that FN treatment is administered on an inpatient basis. Filgrastim and lenograstim 
were assumed to be administered as weight based doses at 5mcg/kg/day. Patient 
weights were reported in three of the studies and a weighted mean was calculated 
to be 72.3kg (SD 14.7kg). (5;37;38) Using this patient weight distribution, the 
following vial size requirements were calculated: 20% of patients weigh <60kg and 
require a single 300mcg vial; 74% of patients weigh 61kg-96kg and require a single 
480mcg vial; and 5% of patients weigh at least 97kg and require two 300mcg vials. 
Similarly for lenograstim, 10% of patients weigh <53kg and require a single 263mcg 
vial; 45% of patients weigh 54-74kg and require a 263mcg vial plus a 105mcg vial; 
and 45% of patients weigh at least 75kg and require two 263mcg vials. Since the G- 
CSF market in the UK is driven by competitive tenders it is common for discounts to 
be provided on list prices. Therefore various discounted prices were considered in a 
sensitivity analysis. 
 
The costs of chemotherapy are dependent on the number of chemotherapy cycles 
received. If a patient dies from an FN event during chemotherapy, no further cycles 
are given and no further costs incurred. Chemotherapy costs vary depending on the 
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regimen. For simplicity the cost of TAC is used at £1,234 per cycle.(39) Costs of 
chemotherapy have been assumed independent of RDI rate. 
 
 
 
RESULTS 
 
Results are presented for a baseline FN risk of 24%, the mean risk for a patient 
receiving TAC chemotherapy.(7) We calculate the incremental costs and QALYs 
compared with a strategy of no G-CSF prophylaxis. These are presented alongside 
the net monetary benefits and incremental cost effectiveness ratio (ICER) in Table 4. 
At this risk level, the ICER for primary prophylaxis with pegfilgrastim is £38,482. The 
cost effectiveness acceptability curve (CEAC) (40) is shown in Figure 3. All strategies 
are presented in the CEAC but only primary and secondary pegfilgrastim and no G- 
CSFs have a probability of being cost effective of over 0.05 so the other strategies are 
very close to the x-axis. With a WTP threshold of between £20,000 and £30,000 per 
QALY secondary prophylaxis with pegfilgrastim is the most cost effective strategy 
over 90% of the time. We also calculated results for the regimen epirubicin- 
docetaxel (ET75) which is reported to have an FN risk of 31% (Table 4). (41;42) At this 
risk level, the ICER for primary prophylaxis with pegfilgrastim is £26,824. 
 
Results are highly sensitive to baseline FN risk. The base case analysis with a WTP 
threshold of £20,000 per QALY demonstrated that for a patient with an FN risk level 
of 11-37% secondary prophylaxis with pegfilgrastim is most cost effective and for 
patients with higher FN risk levels primary prophylaxis with pegfilgrastim becomes 
the most cost effective. Using a WTP threshold of £30,000, primary prophylaxis with 
pegfilgrastim was cost-effective for baseline FN risks greater than 29%. 
 
Deterministic one-way sensitivity analysis on baseline FN risk level was performed for 
a selection of scenarios and results are presented in Figure 4. For a particular 
chemotherapy regimen, the baseline FN risk, and therefore the cost-effectiveness of 
G-CSF prophylaxis, will vary for individual patients depending on patient risk factors 
such as performance status, age, etc. A clinician would be assumed to estimate the 
risk of FN for an individual patient according to factors such as performance status as 
well as the chemotherapy regimen they were receiving. As age increases, there will be 
a decrease in remaining expected QALYs but an increase in expected baseline FN risk 
which impact the cost-effectiveness in opposing directions 
 
The scenario analyses performed demonstrate that age at diagnosis, stage at 
diagnosis, WTP threshold and G-CSF price all significantly affect the level of baseline 
FN risk at which G-CSF prophylaxis becomes cost effective. The scale of the effect 
these variables can have on the ICER is shown in a tornado diagram, Figure 5. 
 
We observe that all the strategies involving the once-daily G-CSFs filgrastim and 
lenograstim are never optimal. Our analysis indicated that pegfilgrastim would 
dominate filgrastim and lenograstim given for 11 days (as pegfilgrastim has lower 
cost and higher efficacy), and had small ICERs compared with 6 day treatment 
courses. As previously mentioned trial evidence relating to using filgrastim or 
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lenograstim for six days is limited and inconclusive. We note that if 6 day filgrastim 
was assumed to be less effective than 11 day filgrastim this would result in lower 
expected QALYs and slightly higher expected costs for 6 day filgrastim compared 
with 11 day filgrastim. As discussed earlier evidence comparing the efficacy of 6 and 
11 day filgrastim/lenograstim is inconclusive but, as an example, if the relative risk of 
FN for 6 day filgrastim versus no G-CSF was 0.8 then primary prophylaxis with 6-day 
filgrastim is associated with an expected 10.102 QALYs and £12,330. 
 
 
 
DISCUSSION 
 
The most cost-effective strategy is dependent on the estimated baseline risk of FN 
for an individual patient, the cost per QALY threshold, patient age and stage at 
diagnosis and G-CSF price. It is noted that in all scenarios the most cost-effective 
strategy was one of primary pegfilgrastim, secondary pegfilgrastim or no G-CSFs. 
Strategies involving 11-day filgrastim or lenograstim were dominated and in no 
scenario was the use of 6-day treatment with filgrastim or lenograstim the most 
cost-effective strategy. 
 
This study had several limitations. Several assumptions had to be made due to 
limitations in the data available. For example UK-specific data was not available for 
all parameter values so data from other countries was used. A statistical analysis 
relating patient age, performance status and chemotherapy to FN risk was not 
available but the modelling would be improved if the relationship between these 
factors was included. The availability of further data reporting FN events with details 
of chemotherapy cycle number and initial FN events would make the modelling 
more robust. 
 
If an FN event leads to reduced RDI then this could lead to higher breast cancer 
recurrence rates. Hence breast cancer treatment costs may be higher for strategies 
which result in more FN events. There is very limited data to estimate the change in 
treatment costs due to low RDI and there is considerable uncertainty surrounding 
the relationship between FN and RDI and RDI and survival. Hence, the modelling of 
costs was simplified by assuming all post-chemotherapy costs were the same 
independent of prophylaxis strategy. This assumption that the post chemotherapy 
costs are the same for all strategies may bias against G-CSF use. 
 
Sensitivity analyses for stage at diagnosis and age at diagnosis demonstrate that for 
some subgroups primary prophylaxis with pegfilgrastim will be the most cost 
effective strategy at lower levels of FN risk. Since the G-CSF market in the UK is 
driven by competitive tenders it is common for discounts to be provided on list 
prices. Including the possible discounting of G-CSFs within the modelling also greatly 
reduces the FN risk threshold at which primary prophylaxis with pegfilgrastim is cost 
effective. The overall decision on whether to use G-CSFs will depend on the 
clinician’s assessment of risk factors for a particular patient. 
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Currently there are two filgrastim biosimilars available in the UK with list prices 
approximately 10% less than the originator filgrastim (Neupogen). (43) A sensitivity 
analysis on cost of filgrastim was performed using a WTP threshold of £20,000. 
Regardless of FN risk level, if the cost of filgrastim is reduced to 50% of list price the 
most cost effective strategies still do not involve filgrastim. As an example, for the 
base case FN risk level of 24%, primary prophylaxis with filgrastim for 6 days 
becomes the most cost effective strategy if the cost of filgrastim discounted to 18% 
of the list price. However, if pegfilgrastim is discounted to 50% of the list price then 
prophylaxis with filgrastim is never the most costs effective even if filgrastim is free. 
 
Published cost-effectiveness analyses (44) (45) for different healthcare systems have 
reached different conclusions regarding the cost-effectiveness of G-CSF prophylaxis 
for febrile neutropenia and have more closely supported international clinical 
guideline recommendations on the use of G-CSFs (7;12). Differences in the 
conclusions of these analyses are due to: the use of different pegfilgrastim efficacy 
values, different costs and care pathways for different countries, and differences 
between the structures of the models used. 
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Figure 1: Factors affecting FN risk and survival 
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Figure 2: Schematic of the decision analytic model 
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Figure 3: Cost Effectiveness Acceptability Curves for base case analysis 
(Base Case: TAC chemotherapy, FN risk level 24%, age 52, stage at diagnosis 2, list price 
GCSFs) 
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Figure 4: Sensitivity Analyses: The G-CSF strategy with highest NMB for different levels of 
baseline FN risk 
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*Base case is WTP of £20,000 per QALY gained, stage 2 at diagnosis, age 52 at diagnosis. 
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Figure 5: Tornado diagram for primary prophylaxis with pegfilgrastim compared to 
secondary prophylaxis with pegfilgrastim 
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Table 1: Relative risk of febrile neutropenia incidence with G-CSF prophylaxis 
 
 
G-CSF prophylaxis Source Relative risk of FN compared with no G-CSF 
prophylaxis, (95% CI), p-value 
Pegfilgrastim Vogel 2005(6), Balducci 
2007(46), Romieu 2007(37), 
Hecht 2009(47) 
0.30 (0.14 to 0.65), p=0.002 
Filgrastim (11 day) Kuderer 2007(23), del Giglio 
2008(48) 
0.57 (0.48 to 0.69), p<0.00001 
Filgrastim (6 day) Assumed same as 11 day 0.57 (0.48 to 0.69), p<0.00001 
Lenograstim (11 day) Kuderer 2007(23) 0.62 (0.44 to 0.88), p=0.007 
Lenograstim (6 day) Assumed same as 11 day 0.62 (0.44 to 0.88), p=0.007 
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Table 2: Relationship between age, prior febrile neutropenia (FN) and relative dose 
intensity (RDI) 
 
 
Proportion of patients with RDI <85% * 
All patients (n=3707) 29.7% 
Age <65 (n=2998) 26.9% 
Age ≥ 65 (n=709) 41.4% 
FN (n not reported) 36.0% 
Odds ratios for risk of reduced RDI* 
Age ≥ 65 vs. age <65 1.51 (95% CI 1.24 to 1.83) 
Prior FN event vs. no prior FN event 1.58 (95% CI 1.20 to 2.10) 
Probability of having a low RDI based on age and prior FN events 
Aged < 65 years , No prior FN  (BR) 24.7% (95% CI 14.9% to 34.5%) 
Aged < 65 years, Prior FN 34.1% ** 
Aged 65 years or over, No prior FN 33.1% ** 
Aged 65 years or over, Prior FN 43.9% ** 
 
* Data from Shayne et al. 2006 (2) 
**Calculated using odds ratio and formula: BR/ (OR (1-BR) +BR) where BR=baseline risk, OR=odds ratio 
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Table 3: Summary of parameters used in model: deterministic values, distribution used in 
PSA, and references 
 
 
Variable Value Distribution Source 
 
Costs 
Cost of pegfilgrastim per injection £    686.38 Assumed fixed BNF (43) 
Cost of filgrastim per injection £ 98.39 Assumed fixed BNF (43)weight based dose 
5mcg/kg/day 
Cost of lenograstim per injection £ 111.83 Assumed fixed BNF (43)weight based dose 
5mcg/kg/day 
Cost of administrating a G-CSF injection £ 21.00 Assumed fixed Curtis 2007 (49) 
Cost of TAC chemotherapy per cycle £ 1,234.00 Assumed fixed Ward et al 2007 (39) 
Cost of hospitalisation per day £    235.00 Assumed fixed Curtis 2007 (49) 
Cost of IV antibiotics during hospitalisation £ 47.23 Assumed fixed BNF(43) 
Cost of daily investigations (per day of 
hospitalisation) 
£ 9.27 Assumed fixed Sweetenham et al 1999 (50) 
uplifted to 2007 
Cost of once-per-FN investigations (per FN) £ 47.86 Assumed fixed Sweetenham et al 1999 (50) 
uplifted to 2007 
Average duration of hospitalisation for an 
FN event in days – breast cancer 
8 
Normal(Mean = 8, Std Dev = 0.2041) 
Kuderer et al 2006(1) 
Rate used for discounting costs and QALYs 0.035 NICE (15) 
 
RDI and mortality inputs 
Probability of dying from an FN event 0.036 Normal(Mean = 0.036, Std Dev = 
0.00357) 
 
Kuderer et al 2006 (1) 
Risk of RDI<85% if <65 years and no FN 0.247 Normal (Mean = 0.247, Std Dev = 0.05) Shayne et al 2006(2) 
Odds ratio for RDI<85% if patient >65 years 1.51 Log-normal (mean of logs=0.4072, sd of 
logs=0.0993) 
Shayne et al 2006 (2) 
Odds ratio of having RDI<85% if patient has 
had FN event 
1.58 Log-normal (mean of logs=0.4472, sd of 
logs=0.1428) 
Shayne et al 2006 (2) 
Hazard Ratio if low RDI (<85%) 1.73 Log-normal (mean of logs=0.5284, sd of 
logs=0.1987) 
Chirivella et al 2009 (31) 
 
FN risk 
Relative risk of an FN event with 
pegfilgrastim primary prophylaxis vs. no G- 
CSF 
 
0.30 
 
 
Log-normal (mean of logs=-1.2807, sd of 
logs=0.3917) 
 
See Table 1 
Relative risk of Neupogen (filgrastim) 11 
days compared with no G-CSF 
Relative risk of Lenograstim compared with 
no G-CSF 
Relative risk of an FN event if patient has 
already had an FN event 
Relative risk of an FN event in cycles 2-6 
compared with cycle 1 
0.57 Log-normal (mean of logs=-0.5664, sd of 
logs=0.0926) 
0.62 Log-normal (mean of logs=-0.4886, sd of 
logs=0.1754) 
9.089 Log-normal (mean of logs=2.1878, sd of 
logs=0.1961) 
0.213 Log-normal (mean of logs=-1.5621, sd of 
logs=0.1635) 
See Table 1 
 
See Table 1 
 
Calculated from data in von 
Minckwitz et al 2008 (21) 
Calculated from data in von 
Minckwitz et al 2008 (21) 
 
Utility multipliers (these are multiplied by 
an age-specific average utility value from 
Kind et al 1998 (32)) 
Breast cancer; undergoing chemotherapy 
treatment 
Breast cancer; undergoing chemotherapy 
treatment - multiplier 
 
 
 
 
0.7 Range 0.5-1 Hillner et al 1992 (33) 
 
0.843 Beta(9.9, 1.8) 95% CI 0.6-0.98 
FN event hospitalisation 0.33 Range 0.24-0.42 Brown et al 2001 (35); 
Brown & Hutton 1998 (34) 
FN event hospitalisation - multiplier 0.398 Beta(30.7, 46.5) 95% CI 0.29-0.51 
 
First year post chemo and subsequent 
years 2-5 
0.855 Hind et al 2007 (36) 
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Cancer survivors after year 5 0.879  Hind et al 2007 {36) 
Years 20 onwards {from  diagnosis), Utility 0.94  Hind et al 2007{36) 
multiplier for  disease free  survival 
Utility multiplier for  local  regional BC 
 
0.74 
Beta{3.44, 0.21) 
Beta{1.36, 0.48) 
 
Hind et al 2007 {36) 
Utility multiplier for  metastatic BC 0.5 Beta{2.75, 2.75) Hind et al 2007 {36) 
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Table 4: PSA results 
 
  
 
Cost (£) QALYs 
 
Incr.  Incr. 
Cost (£) QALYs 
Incr NMB 
(£), 
WTP=£20K 
Incr NMB 
(£), 
WTP=£30K 
 
 
ICER* 
 
Base Case: TAC chemotherapy, FN risk level 24%, age 52, stage at diagnosis 2 
No GCSFs 
Secondary 
prophylaxis with 
lenograstim for 11 
days 
Secondary 
prophylaxis with 
lenograstim for 6 
days 
Secondary 
prophylaxis with 
filgrastim for 11 days 
Secondary 
prophylaxis with 
filgrastim for 6 days 
Secondary 
prophylaxis with 
pegfilgrastim 
Primary prophylaxis 
with lenograstim for 
11 days 
Primary prophylaxis 
with lenograstim for 
6 days 
Primary prophylaxis 
with filgrastim for 11 
days 
Primary prophylaxis 
with filgrastim for 6 
days 
Primary prophylaxis 
with pegfilgrastim 
8,282 10.060 
 
 
 
 
9,250 10.083 
 
 
 
 
8,744 10.083 
 
 
9,134 10.084 
 
 
8,679 10.084 
 
 
8,556 10.103 
 
 
16,607 10.136 
 
 
12,637 10.136 
 
 
15,715 10.138 
 
 
12,147 10.138 
 
11,841 10.188 
- - 
 
 
 
 
968 0.023 
 
 
 
 
462 0.023 
 
 
852 0.024 
 
 
397 0.024 
 
 
274 0.042 
 
 
8,326 0.075 
 
 
4,355 0.075 
 
 
7,434 0.077 
 
 
3,865 0.077 
 
3,559 0.128 
- 
 
 
 
 
- 509 
 
 
 
 
- 3 
 
 
- 382 
 
 
73 
 
 
570 
 
 
- 6,816 
 
 
- 2,846 
 
 
- 5,891 
 
 
- 2,322 
 
- 1,008 
- 
 
 
 
 
- 279 
 
 
 
 
227 
 
 
- 147 
 
 
308 
 
 
992 
 
 
- 6,061 
 
 
- 2,091 
 
 
- 5,120 
 
 
- 1,551 
 
268 
 
 
 
 
 
dominated 
 
 
 
 
dominated 
dominated 
dominated 
£  6,500 
dominated 
dominated 
dominated 
dominated 
 
£ 38,482 
 
Second Example Analysis: ET chemotherapy, FN risk level 31%, age 52, stage at diagnosis 2 
No GCSFs Secondary 
prophylaxis with 
pegfilgrastim 
Primary prophylaxis 
with pegfilgrastim 
8,658 9.989 
 
 
8,910 10.059 
 
11,910 10.170 
- - 
 
 
253 0.069 
 
3,252 0.181 
- 
 
 
1,131 
 
368 
- 
 
 
1,823 
 
2,178 
 
 
 
 
£  3,651 
 
£ 26,824 
* ICERs are only presented for strategies on the cost effectiveness frontier. The ICER is calculated compared to the next 
less effective strategy on the cost effectiveness frontier. 
